Akouos Reports First Quarter 2021 Financial Results and Provides Business Updates
Akouos, Inc. (Nasdaq: AKUS) announced key developments including the appointment of Dr. Kathy Reape as chief development officer, enhancing its leadership team. The FDA granted both Orphan Drug and Rare Pediatric Disease designations for AK-OTOF, targeting otoferlin gene-mediated hearing loss, with plans for an IND submission in 2022. Financially, the company reported a net loss of $16.1 million for Q1 2021, an increase from $10.4 million in Q1 2020, alongside R&D expenses rising to $11.3 million. Akouos maintains a cash position of $286.6 million to fund operations for at least two years.
- Appointment of Kathy Reape as chief development officer brings over 20 years of experience.
- AK-OTOF granted Orphan Drug and Rare Pediatric Disease designations by the FDA.
- Plans for IND submissions for both AK-OTOF and AK-antiVEGF in 2022.
- Completion of infrastructure build for internal cGMP manufacturing to support clinical development.
- Net loss increased to $16.1 million in Q1 2021, up from $10.4 million in Q1 2020.
- R&D expenses increased to $11.3 million, indicating rising operational costs.
- Leadership team expanded with appointment of Kathy Reape, M.D. as chief development officer
- AK-OTOF granted both Orphan Drug Designation and Rare Pediatric Disease Designation by FDA and is on track for planned IND submission in first half of 2022
- Nonclinical data supporting future clinical development of AK-OTOF and AK-antiVEGF presented at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting
- Construction for an internal cGMP manufacturing facility completed, and expansion of laboratory footprint underway, contributing to continued infrastructure build to support future development activities
BOSTON, May 13, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the first quarter ended March 31, 2021 and provides business updates.
“We continue to demonstrate our leadership in the field of inner ear genetic medicines. Recently, FDA granted AK-OTOF, our lead product candidate, what we believe are the first Orphan Drug and Rare Pediatric Disease designations for a genetic form of hearing loss. At the ASGCT Annual Meeting, our team presented nonclinical data demonstrating the unique applicability of our genetic medicine platform to potentially restore, improve, and preserve physiologic hearing for a monogenic condition and a condition of complex etiology,” said Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos. “These accomplishments have been made possible by our team of leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy, including the recent addition of Dr. Kathy Reape as chief development officer. We continue to build our team’s capabilities, infrastructure, and facilities to support our planned IND submissions for AK-OTOF and AK-antiVEGF in 2022, and are progressing our earlier stage programs towards candidate selection or target announcement.”
Business Highlights
- Appointment of Kathy Reape, M.D. as chief development officer – Dr. Kathy Reape joined Akouos as chief development officer and brings over 20 years of experience in clinical drug development and medical affairs to Akouos, most notably from her recent role as chief medical officer of Spark Therapeutics.
- Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA for AK-OTOF – AK-OTOF is a gene therapy intended for the treatment of otoferlin gene (OTOF)-mediated hearing loss, a condition that often results in Severe to Profound sensorineural hearing loss from birth and does not currently have any pharmacologic treatment options available. The receipt of these designations could support acceleration of development of AK-OTOF.
- Presented nonclinical data at the ASGCT 24th Annual Meeting reflecting broad applicability of genetic medicine platform to treat inner ear conditions – In May 2021, Akouos presented nonclinical data that support the future clinical development for both AK-OTOF and AK-antiVEGF, a gene therapy intended for the treatment of vestibular schwannoma, at the ASGCT 24th Annual Meeting. The digital presentations are located at https://akouos.com/gene-therapy-resources/.
- Continued advancement of both AK-OTOF and AK-antiVEGF towards expected IND submissions in 2022 – Akouos continues to make progress towards an investigational new drug application (IND) submission for AK-OTOF planned in the first half of 2022. The Company expects to submit an IND for AK-antiVEGF in 2022. Both programs utilize key components of Akouos’s genetic medicine platform, which incorporates a proprietary AAVAnc capsid library, including AAVAnc80, and a novel delivery approach that leverages minimally-invasive surgical techniques familiar to otologic surgeons.
- Building infrastructure to support future development – Akouos expanded its facility at 645 Summer Street in Boston, MA to support additional research, development, and manufacturing activities. In 2021, the Company plans to complete build of infrastructure and capabilities to enable internal cGMP manufacturing expected to support clinical development of product candidates, at the anticipated commercial scale.
First Quarter 2021 Financial Results
- Cash Position – Cash, cash equivalents, and marketable securities were
$286.6 million as of March 31, 2021, as compared to$308.0 million as of December 31, 2020. Akouos expects its cash balance to fund operations for at least the next two years. - Research and Development (R&D) Expenses – R&D expenses were
$11.3 million for the first quarter ended March 31, 2021, compared to$8.0 million for the same period in 2020. The increase was primarily due to the increased efforts in IND-enabling studies for AK-OTOF and AK-antiVEGF and the growth in the number of R&D employees and their related activities, as well as the expense allocated to R&D related to Akouos’s leased facilities. - General and Administrative (G&A) Expenses – G&A expenses were
$4.9 million for the first quarter ended March 31, 2021, as compared to$2.5 million for the same period in 2020. The increase was primarily due to the growth in the number of G&A employees and other administrative expenses related to operating as a public company, as well as the expense allocated to G&A related to Akouos’s leased facilities. - Net Loss – Net loss was
$16.1 million , or$0.47 loss per share, for the first quarter ended March 31, 2021, compared to$10.4 million , or$14.74 loss per share, for the same period in 2020.
About Akouos
Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the initiation, plans, and timing of our future clinical trials and our research and development programs, the timing of our IND submissions for AK-OTOF and AK-antiVEGF, our expectations regarding our manufacturing capabilities and timelines, and the period over which we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our limited operating history; uncertainties inherent in the development of product candidates, including the initiation and completion of nonclinical studies and clinical trials; whether results from nonclinical studies will be predictive of results or success of clinical trials; the timing of and our ability to submit applications for, and obtain and maintain regulatory approvals for, our product candidates; our expectations regarding our regulatory strategy; our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential addressable patient population for our product candidates; our commercialization, marketing, and manufacturing capabilities and strategy; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to identify additional products, product candidates, or technologies with significant commercial potential that are consistent with our commercial objectives; the impact of government laws and regulations; risks related to competitive programs; the potential that our internal manufacturing capabilities and/or external manufacturing supply may experience delays; the impact of the COVID-19 pandemic on our business, results of operations, and financial condition; our ability to maintain and establish collaborations or obtain additional funding; and other factors discussed in the “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission, and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Condensed Consolidated Balance Sheet Data
(Unaudited)
(in thousands)
| March 31, 2021 | December 31, 2020 | |||||||
| Cash, cash equivalents and marketable securities | $ | 286,619 | $ | 308,010 | ||||
| Total assets | 321,859 | 333,350 | ||||||
| Total liabilities | 25,057 | 22,736 | ||||||
| Total stockholders’ equity | 296,802 | 310,614 | ||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per share data)
| Three months ended March 31, | ||||||||
| 2021 | 2020 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 11,258 | $ | 8,034 | ||||
| General and administrative | 4,890 | 2,504 | ||||||
| Total operating expenses | 16,148 | 10,538 | ||||||
| Loss from operations | (16,148 | ) | (10,538 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 509 | 100 | ||||||
| Other expense, net | (447 | ) | (2 | ) | ||||
| Total other income, net | 62 | 98 | ||||||
| Net loss | $ | (16,086 | ) | $ | (10,440 | ) | ||
| Weighted‑average common shares outstanding, basic and diluted | 34,284,419 | 708,204 | ||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.47 | ) | $ | (14.74 | ) | ||
Contacts
Media:
Katie Engleman, 1AB
katie@1abmedia.com
Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com
FAQ
What are the key developments Akouos reported in May 2021?
What is the significance of the FDA designations granted to AK-OTOF?
When does Akouos plan to submit the IND for AK-OTOF?
What were Akouos's financial results for Q1 2021?
How much cash does Akouos have and how long can it fund its operations?
